Evaluating ALK Inhibitors in Treatment Sequencing and Testing

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

Full overall survival results with amivantamab plus lazertinib from the Asia cohort of the MARIPOSA trial will be shared at a future medical conference.

Jacob Sands, MD

August 4th 2025

Crizotinib Falls Short on DFS and OS Improvements in ALK+ NSCLC

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Jax DiEugenio

September 9th 2025

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

When compared with observation, adjuvant crizotinib did not improve disease-free survival or overall survival in ALK-positive NSCLC.

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Stephen V. Liu, MD;Joshua K. Sabari, MD

June 23rd 2025

Dato-DXd Increases Intracranial Responses/PFS in NSCLC With Brain Mets

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Kyle Doherty

Concurrent Durvalumab Plus Chemo/RT Does Not Improve Efficacy in Stage III NSCLC

The median CNS PFS with Dato-DXd was 5.0 months vs 3.0 months with docetaxel in patients with NSCLC who have brain metastases.

Ariana Pelosci

Amivantamab Combo Significantly Improves OS in Asian EGFR+ NSCLC Population

For patients with unresectable stage III NSCLC, concurrent durvalumab with chemotherapy/radiation did not show an efficacy improvement.

Related Content

Tim Cortese

September 12th 2025

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

Full overall survival results with amivantamab plus lazertinib from the Asia cohort of the MARIPOSA trial will be shared at a future medical conference.

Jacob Sands, MD

August 4th 2025

Crizotinib Falls Short on DFS and OS Improvements in ALK+ NSCLC

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Jax DiEugenio

September 9th 2025

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

When compared with observation, adjuvant crizotinib did not improve disease-free survival or overall survival in ALK-positive NSCLC.

Stephen V. Liu, MD;Joshua K. Sabari, MD

June 23rd 2025

Dato-DXd Increases Intracranial Responses/PFS in NSCLC With Brain Mets

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Kyle Doherty

Concurrent Durvalumab Plus Chemo/RT Does Not Improve Efficacy in Stage III NSCLC

The median CNS PFS with Dato-DXd was 5.0 months vs 3.0 months with docetaxel in patients with NSCLC who have brain metastases.

Ariana Pelosci